Interesting ImagesFusion 68Ga–Prostate-Specific Membrane Antigen PET/MRI on Postoperative Surveillance of Juvenile Nasal AngiofibromaSakthivel, Pirabu MS, DNB∗; Thakar, Alok MS, FRCS∗; Arunraj, Sreedharan Thankarajan MD†; Bhalla, Ashu Seith MD‡; Kumar, Rakesh MD†Author Information From the Departments of ∗Otorhinolaryngology & Head and Neck Surgery †Nuclear Medicine ‡Radiology, All India Institute of Medical Sciences, New Delhi, India. Received for publication December 10, 2019; revision accepted February 23, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Rakesh Kumar, MD, Division of Diagnostic Nuclear Medicine, Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi 110029, India. E-mail: firstname.lastname@example.org. Clinical Nuclear Medicine: July 2020 - Volume 45 - Issue 7 - p e325-e326 doi: 10.1097/RLU.0000000000003041 Buy Metrics Abstract Prostate-specific membrane antigen (PSMA) is expressed universally in juvenile nasopharyngeal angiofibroma (JNA). As contrast enhancement of postoperative scar is common with contrast-enhanced MRI (CEMRI), diagnosis of residual/recurrent JNA remains perplexing. Prostate-specific membrane antigen PET targets only the neovasculature and may aid in resolving this dilemma. Positive contrast enhancement on CEMRI was noted in a patient after 30 years of initial surgery, simulating recurrence. However, there was no abnormal uptake in PSMA scan, which was confirmed by biopsy as postoperative fibrosis. 68Ga-PSMA PET/MRI fusion may be an easy and novel technique to aid in differentiating residual/recurrent disease from surgical site reparative tissue. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.